[Prospects and achievements of genetic engineering in development of antiviral vaccines].
Proceeding from the known data various theoretical and experimental approaches to the construction of gene-engineering vaccines are considered. Gene-engineering subunit vaccines of the first generation are based on isolation of the genes coding for the synthesis of full length capsid proteins with the main antigenic determinants and their subsequent expression in suitable recipient cells. Initial idea of the microbiological synthesis as the main way for production of any antiviral vaccines was not confirmed by the later development. Now for this type of vaccines eucaryotic systems are widely employed using the animal virus vectors and the animal cell cultures. Gene-engineering subunit vaccine of the second generation appears to be a chimeric protein with built-in antigenic determinants of different viruses and maximal immunogenicity in monomeric form. The last point reopens the perspective to use a microbiological synthesis for the production of antiviral vaccines. Besides that the chemically synthesized polypeptide antiviral vaccine will be used widely. In gene-engineering subunit vaccines of the third generation it is possible to use not the natural antigenic determinants which often are characterized by high level of the primary structure changes but artificial (non-natural) antigens, that are the capsid protein conservative regions which under natural conditions of infection or immunization do not induce the protective antiviral antibodies. The recombinant DNA technology in addition to subunit type vaccine allows to construct living vaccines which represent a DNA-containing attenuated virus with build-in natural or synthetic gene of the capsid or chimeric protein with antigenic determinants of another viral species.
D000818:Animals; D000956:Antigens, Viral / Q000096:biosynthesis / Q000276:immunology; D005537:Aphthovirus / Q000235:genetics / Q000276:immunology; D002213:Capsid / Q000096:biosynthesis / Q000276:immunology; D002417:Cattle; D004926:Escherichia coli / Q000235:genetics* / Q000378:metabolism; D005818:Genetic Engineering; D006515:Hepatitis B virus / Q000235:genetics / Q000276:immunology; D006801:Humans; D007252:Influenza Vaccines; D009975:Orthomyxoviridae / Q000235:genetics / Q000276:immunology; D010957:Plasmids; D014764:Viral Proteins / Q000096:biosynthesis* / Q000276:immunology; D014765:Viral Vaccines
D000956:Antigens, Viral; D007252:Influenza Vaccines; D014764:Viral Proteins; D014765:Viral Vaccines
Perspektivy i dostizheniia v sozdanii genno-inzhenernykh protivovirusnykh vaktsin.